Jecho Biopharmaceuticals Co., Ltd.

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 1…

This early-stage study tests an injection called JL18008 in HIV patients whose immune systems haven't fully recovered despite standard treatment. The goal is to see if it's safe and can improve immune function. About 52 adults aged 18-65 with well-controlled HIV but low CD4 count…

This study tests an experimental drug called JL18008 in people with HIV whose immune systems haven't fully recovered despite standard treatment. About 30 adults will receive either the drug or a placebo as a weekly injection for 4 weeks, while continuing their regular HIV medicat…

This early-phase study tests a new drug called JL19001, given alone or with a standard therapy (BCG), for people with high-risk non-muscle invasive bladder cancer. The main goals are to check safety, find the best dose, and see how the body responds. About 18 adults will take par…